Summary statistics - quantitative results

EQA round: TDM2/23 - Therapeutic Drugs

Deadline: 6.10.2023

Setup: groups - measurement principle; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D_{max} = acceptable difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	CVP = consensus of all participants	UL = upper limit
N_{tot} = total number of the results	U_{AV} = expanded uncertainty of the assigned value (k = 2)	N_{eva} = number of the results assessed
N_{out} = number of the results removed before calculation		N_{suc} = number of successful results
		S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]	Traceability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
Set 1																						
(81) **Digoxin**	[µg/L]				15							0								15	14	93
Sample A1		0,957	0,18	19	15							0			CRV 0,979	0,013	36%	0,626	1,34	15	14	93
(4) LIA, ILMA		0,88	0,31	35	8	0														8		
(6) Immunoturbidimetry, KIMS		1,04	0,089	8,6	5	0														5		
Other					2	0														2		
														2x 2								
Sample B1		1,52	0,27	18	15							0			CRV 1,57	0,04	36%	1	2,14	15	14	93
(4) LIA, ILMA		1,47	0,34	23	8	0														8		
(6) Immunoturbidimetry, KIMS		1,72	0,056	3,2	5	0														5		
Other					2	0														2		
														2x 2								
(84) **Phenobarbital**	[mg/L]				6							6	6	100						0		
Sample A1												6	6	100						0		
Other					6	0						6										
							4x 4, 2x 6															
Sample B1												6	6	100						0		
Other					6	0						6										
							4x 4, 2x 6															
(85) **Phenytoin**	[mg/L]				2							2	2	100						0		
Sample A1												2	2	100						0		
Other					2	0						2										
							1x 2, 1x 4															
Sample B1												2	2	100						0		
Other					2	0						2										
							1x 2, 1x 4															
(86) **Carbamazepin**	[mg/L]				11							11	11	100						0		
Sample A1												11	11	100						0		
Other					11	0						11										
							1x 1, 4x 2, 3x 4, 3x 6															
Sample B1												11	11	100						0		
Other					11	0						11										
							1x 1, 4x 2, 3x 4, 3x 6															
(88) **Valproic acid**	[mg/L]				13							13	12	92						0		
Sample A1		72,7	7,5	10	13		CVP 72,5	1,6	20%	58	87	13	12	92						0		
(2) EIA (EMIT, CEDIA)		77	4,5	5,9	5	0						5										
(6) Immunoturbidimetry, KIMS		69,8	2,7	3,9	5	0						5										
Other					3	0						3										
							1x 1, 2x 4															

Summary statistics - quantitative results

EQA round: TDM2/23 - Therapeutic Drugs

Deadline: 6.10.2023

Setup: groups - measurement principle; Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]	Traceability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
Sample B1		38,8	3,4	8,8	13		CVP	39,4	0,75	20%	31,5	47,3	13	13	100							0		
(2) EIA (EMIT, CEDIA)		40,9	1,3	3,3	5	0							5											
(6) Immunoturbidimetry, KIMS		37	1,9	5	5	0							5											
Other					3	0							3											
							1x 1, 2x 4																	
(91) **Lithium**	[mmol/L]				2								0									2	2	100
Sample A1													0									2	2	100
Other					2	0																2		
																2x 99								
Sample B1													0									2	2	100
Other					2	0																2		
																2x 99								
(82) **Theophylline**	[mg/L]				4								0									4	4	100
Sample A1													0									4	4	100
Other					4	0																4		
																2x 2, 2x 4								
Sample B1													0									4	4	100
Other					4	0																4		
																2x 2, 2x 4								
Set 2																								
(89) **Amicacin**	[mg/L]				6								6	6	100							0		
Sample A2		4,1	0,3	7,2	6		CVP	3,88	0,2	20%	3,1	4,66	6	6	100							0		
(2) EIA (EMIT, CEDIA)		4,1	0,3	7,2	5	0							5											
Other					1	0							1											
							1x 6																	
Sample B2		12,5	1	8	6		CVP	13,2	0,25	20%	10,5	15,9	6	6	100							0		
(2) EIA (EMIT, CEDIA)		12,3	0,63	5,1	5	0							5											
Other					1	0							1											
							1x 6																	
(90) **Gentamicin**	[mg/L]				13								13	12	92							0		
Sample A2		12,9	1,4	11	13								13	13	100							0		
(4) LIA, ILMA		12,7	0,86	6,8	5	0	CVP	13,7	0,51	31%	9,45	18	5											
Other					8	0							8											
							1x 1, 4x 2, 2x 6, 1x 6/60																	
Sample B2		15,4	2,7	18	13								13	12	92							0		
(4) LIA, ILMA		14,5	1,1	7,4	5	0	CVP	16,4	0,69	31%	11,3	21,5	5											
Other					8	0							8											
							1x 1, 4x 2, 2x 6, 1x 6/60																	
(93) **Methotrexate**	[µmol/L]				5								5	5	100							0		
Sample A2													5	5	100							0		
Other					5	0							5											
							1x 2, 4x 4																	
Sample B2													5	5	100							0		
Other					5	0							5											
							1x 2, 4x 4																	

Summary statistics - quantitative results

EQA round: TDM2/23 - Therapeutic Drugs

Deadline: 6.10.2023

Setup: groups - measurement principle; Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]	Traceability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(92) **Vankomycin**	[mg/L]				14								14	13	93							0		
Sample A2		35,4	3	8,5	14		CVP	35,1	0,9	28%	25,2	45	14	14	100							0		
(4) LIA, ILMA		36,5	0,78	2,1	6	0							6											
Other					8	0							8											
							1x 1, 4x 2, 3x 6																	
Sample B2		14,4	0,94	6,6	14		CVP	14,3	0,36	28%	10,2	18,4	14	13	93							0		
(4) LIA, ILMA		14,4	0,2	1,4	6	0							6											
Other					8	0							8											
							1x 1, 4x 2, 3x 6																	